|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,766 GBX | +2.11% |
|
-0.45% | +21.81% |
| 09:35am | GSK Regarding Ruling By Delaware State Court On Zantac Litigation Will Immediately Seek Appeal | RE |
| 31/05 | US FDA approves Moderna's RSV vaccine, its second marketed product | RE |
May 17 (Reuters) - GSK plc:
* GSK: AGREED TO SELL 385,320,110 ORDINARY SHARES IN HALEON AT A PRICE OF 324 PENCE PER SHARE RAISING GROSS PROCEEDS OF APPROXIMATELY £1,248M
* GSK: FOLLOWING SETTLEMENT OF PLACING, GSK WILL HAVE FULLY EXITED ITS POSITION AND WILL NO LONGER HOLD ANY ORDINARY SHARES IN HALEON Source text for Eikon: Further company coverage:
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,766 GBX | +2.11% | -0.45% | 91.66B | ||
| 325.1 GBX | +0.12% | +0.65% | 37.78B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +21.81% | 91.66B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
GSK PLC 
